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A Response to
Commentary: Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene
expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm
shift
by Banas, S. M., Diaz, S. L., Doly, S., Belmer, A., and Maroteaux, L. (2015). Front. Behav. Neurosci.
9:207. doi: 10.3389/fnbeh.2015.00207
Hertz et al. (2015) provided data indicating that the indisputable SERT inhibition caused by SSRIs
is an epiphenomenon. Instead we pointed toward acute and chronic effects of fluoxetine on 5-
HT2B receptor stimulation in astrocytes (in culture or freshly isolated from brains of mice treated
with fluoxetine for 14 days). Stimulation by fluoxetine of the astrocytic 5-HT2B receptor causes
a multitude of effects that in astrocyte cultures could be prevented by drug- or siRNA-induced
5-HT2B receptor inhibition (Figure 1). This stimulation activates complex signaling pathways,
including EGF receptor transactivation, a signal pathway in which a G-protein-coupled receptor
(GPCR) signal leads to release of a growth factor, which activates the EGF receptor-tyrosinekinase
in the same or adjacent cells. Astrocytes express a number of GPCRs and play key roles in brain
function (Hansson and Rönnbäck, 2004; Fields, 2009).The autocrine effects of growth factor release
may regulate gene expression and alter cell functions in the astrocytes themselves and the paracrine
effects provide opportunities for effects on their neuronal neighbors. Our studies in mice treated
with fluoxetine for 2 weeks showed multiple gene upregulations and editings (Li et al., 2012;
Hertz et al., 2015), which altered the function of the gene product in kainate receptors, 5-HT2
receptors, phospholipase cPLA2, a Ca2+ L-channel gene and nucleoside transporter genes. These
changes occurred mainly in astrocytes but some were neuronal. They occurred together with effects
on metabolism of glucose and glycogen and turnover of glutamate and GABA, consistent with
evidence of increased glutamatergic activity and decreased GABA-ergic activity in patients suffering
from major depression, which are reverted by successful therapy; similarly, glucose metabolism is
decreased in depressed patients and increases following treatment (Hertz et al., 2015).
Hertz et al. Response to Banas Commentary
A commentary by Banas et al. (2015) claim that we forgot
important information provided by Diaz et al. (2012), including
absence of antidepressant effects of fluoxetine or the 5-HT2B
agonist BW723C86 in mice lacking the serotonin transporter
(SERT) or differentiated serotonergic neurons. They allege that
these data rule out that the antidepressant effects of fluoxetine or
BW723C86 could be SERT-independent (as claimed by us) and
show that serotonergic neurons expressing SERT are necessary
for the 5-HT2B receptor effects exerted by fluoxetine (and other
5-HT2B receptor agonists). They further remind us that Launay
et al. (2006) in neuronal cultures from raphe nuclei demonstrated
5-HT2B receptor-mediated control of SERT activity via 5-HT2B
receptor-promoted SERT phosphorylations. This should explain
the finding by Diaz et al. (2012) that there are no antidepressant
effects of either fluoxetine or BW723C86 in mice knocked-out
for SERT or lacking differentiated serotonin neurons. These data
should also rule out that the antidepressant effects of 5-HT2B
agonists, including fluoxetine, could be independent of SERT and
explain the conclusion by theMaroteaux group (Diaz et al., 2012)
that fluoxetine acts by 5-HT2B receptor-mediated regulation of
SERT in a cell autonomous manner.
We were well aware of the lack of antidepressant effect
in SERT knock-outs described by Diaz et al. (2012) and of
their reference to the paper by Launay et al. (2006), but did
not comment on these points, because they are irrelevant.
The lack of effect in the knock-outs does not prove any
dependence on SERT, because Qu et al. (2005) showed that the
direct DOI-mediated stimulation of 5-HT2 receptor activation
of phospholipase A2 (cPLA2) and subsequent arachidonic acid
release and metabolism seen in normal mice is abolished in mice
lacking SERT. There is no information in the literature that
DOI should interact with SERT. Although Qu et al. indicated
DOI as a 5-HT2A/C agonist it also activates the 5-HT2B receptor
(Pineda-Farias et al., 2015). Stimulation of this receptor is
the most likely reason for the response in wild-type animals,
because fluoxetine acutely stimulates astrocytic 5-HT2B receptors
in cultured astrocytes (Li et al., 2008; Qiao et al., 2015) and
after chronic administration (14 days) to mice upregulates this
receptor in astrocytes but not in neurons (Li et al., 2012; Hertz
et al., 2015). Moreover, cPLA2-mediated signal transduction is
increased by acute fluoxetine administration in unanesthetized
rats (Qu et al., 2003) and phospholipase A2 activity is potently
stimulated by the SSRI sertraline in yeast (Rainey et al., 2010).
Since direct stimulation with an agonist has no effect in these
animals, the lack of fluoxetine effect in the knockouts does not
prove fluoxetine dependence on SERT in adult brain.
With respect to the paper by Launay et al. it 2006 deals with
extremely young cells. It does therefore not show that fluoxetine
stimulates the 5-HT2B receptor in mature individuals, because
Homberg et al. (2011) and Sarkar et al. (2014) have shown that
the serotonergic system in the immature brain functions in a
completely different manner than in the mature brain.
Banas et al. also claim we changed results. However, the
figure in Hertz et al. (2012) and in Kong et al. (2002) is—
of course—the same and any reader has the opportunity to
calculate Ki values based on the graph and the concentrations
of mesulergine. The Zhang et al. (2010) paper, referred to
FIGURE 1 | Phosphorylation of ERK1/2, a known target of 5-HT2B
receptor stimulation in astrocytes. After treatment with
phosphate-buffered saline, PBS (Control), transfection solution without siRNA
(siRNA (−)) or siRNA specific to 5-HT2B receptor [siRNA (+)], culturing of well
differentiated astrocytes (at least 3 weeks in culture and treated with dibutyryl
cAMP [dBcAMP]), was continued for another week. Since 5-HT2B receptor
expression in the cultures had been normal until the exposure to siRNA the
result indicates an effect on mature astrocytes. This contrasts the
non-conditional gene knockouts of intact mice used by Diaz et al. (2012),
where effects during development cannot be ruled out. For the
phosphorylation experiments, the cells were incubated for 20min in
serum-free medium in the absence of any drug (Control) or in the presence of
10µM fluoxetine. (1) Immunoblot showing gene expression of phosphorylated
and non-phosphorylated ERK 1 and 2 (p-ERK1 and ERK1 and p-ERK2 and
ERK2) from representative experiments. Similar results were obtained in three
independent experiments. Average ERK phosphorylation was quantitated as
ratios between p-ERK1 and ERK1 (2) and between p-ERK2 and ERK2 (3).
SEM values are indicated by vertical bars. * Indicates statistically significant
(P < 0.05) difference from all other groups for ERK1 and ERK2. (From Li et al.,
2008).
in the Banas commentary clearly indicates the difference
between SSRI affinity during acute and chronic treatment.
There is no major difference between the acute affinity found
by ourselves and others, and we are the only authors who
have measured affinities for SSRIs in chronically treated cells.
The suggestion that effects on muscarinic acetylcholine and
histamine receptors or other monoamine transporters should
explain our observations independently of “putative” direct
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agonist effects at 5-HT2B receptors is invalidated by the
observation by Li et al. (2008) that “ERK phosphorylation
was abolished by SB204741, a universal 5-HT2 receptor
antagonist, and in 5-HT2B receptor-depleted cells (see Figure 1),
but unaffected by 5-HT2A or 5-HT2C receptor antagonists.”
Fluoxetine stimulation of astrocytic 5-HT2B receptors was
confirmed by Qiao et al. (2015).The “putative” receptors were
demonstrated on both well-differentiated astrocyte cultures and
freshly isolated astrocytes (Li et al., 2008, 2012; Peng et al., 2010;
Zhang et al., 2010).
The commentary by Banas et al. has accordingly not altered
our original conclusions but rather strengthened it.
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